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Aims Clinical trials suggest that intracoronary delivery of autologous bone marrow-derived cells (BMCs) 1–7 days post-acute
myocardial infarction (AMI) may improve left ventricular (LV) function. Earlier time points have not been evaluated. We
sought to determine the effect of intracoronary autologous BMC on LV function when delivered within 24 h of suc-
cessful reperfusion therapy.
Methods
and results
A multi-centre phase II randomized, double-blind, and placebo-controlled trial. One hundred patients with anterior
AMI and significant regional wall motion abnormality were randomized to receive either intracoronary infusion of
BMC or placebo (1:1) within 24 h of successful primary percutaneous intervention (PPCI). The primary endpoint
was the change in left ventricular ejection fraction (LVEF) between baseline and 1 year as determined by advanced car-
diac imaging. At 1 year, although LVEF increased compared with baseline in both groups, the between-group difference
favouring BMC was small (2.2%; 95% confidence interval, CI: 20.5 to 5.0; P ¼ 0.10). However, there was a significantly
greater myocardial salvage index in the BMC-treated group compared with placebo (0.1%; 95% CI: 0.0–0.20;
P ¼ 0.048). Major adverse events were rare in both treatment groups.
Conclusion The early infusion of intracoronary BMC following PPCI for patients with AMI and regional wall motion abnormality
leads to a small non-significant improvement in LVEF when compared with placebo; however, it may play an important
role in infarct remodelling and myocardial salvage.
Clinical trial
registration
Clinicaltrials.gov NCT00765453 and EudraCT 2007-002144-16.
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Introduction
Cardiovascular disease is the leading cause of death in the developed
world, with global deaths due to coronary artery disease estimated
to increase from 7.3 million in 2008 to 25 million by 2020.1 Despite
significant improvement in outcome of acute myocardial infarction
(AMI) with the introduction of primary percutaneous coronary
intervention (PPCI), 30-day mortality is still estimated at 12%.2
While PPCI leads to reduced ischaemia, it is also associated with
ischaemia-reperfusion injury which can account for up to 50% of fi-
nal infarct size.3 Therefore, this improvement in survival may be as-
sociated with a relative increase in heart failure morbidity in patients
with significant myocardial damage.
Preclinical studies have suggested that early delivery of bone
marrow-derived cells (BMCs) following acute myocardial ischaemia
results in reduction of infarct size.4 A number of phase I/II clinical
trials assessing the safety and feasibility of autologous BMC delivery
to the infarct zone after successful reperfusion of AMI have re-
ported variable results5– 10 and recent meta-analyses have demon-
strated small improvements in left ventricular ejection fraction
(LVEF).11 The optimal timing of cell delivery has not been estab-
lished. Subgroup analysis of the REPAIR-AMI12 trial showed that
the greatest benefit in LVEF was achieved with cell delivery at 5–
7 days post-PPCI. The more recent TIME and LATE-TIME studies
failed to show improvement in LVEF with cells delivered 3–7 days
and 2–3 weeks post-AMI, respectively.13,14 Cells delivered at 24 h
have also shown no improvement in LVEF.9 Concern regarding
the safety of early cell delivery, 3–5 h post-reperfusion used in pre-
clinical studies,4 has prevented investigation of an earlier time point
in clinical studies. Assessment of ‘early’ cell delivery is essential
in evaluating if cell therapy can be incorporated into the standard
hospital care for patients with AMI.
REGENERATE-AMI is a multi-centre double-blind, randomized,
and placebo-controlled trial designed to determine for the first
time if early delivery of BMC following AMI is safe, efficacious
in the improvement of left ventricular (LV) function and feasible,
in the context of standard inpatient care for AMI.
Methods
Study design and participants
This is a multi-centre double-blinded, randomized, and placebo-
controlled trial to determine if early intracoronary infusion of autologous
bone marrow cells following AMI is safe, feasible and improves LVEF. The
trial was approved by an independent ethics committee and registered at
approved registries (ClinicalTrials.gov, NCT00765453 and EudraCT:
2007-002144-16). The full protocol has been previously published.15
Recruitment was from five centres (see Supplementary material online,
Methods). Participants included in the trial had a diagnosis of acute anter-
ior myocardial infarction (ST elevation in at least two contiguous anterior
leads ≥0.2 mV), resultant significant anterior wall motion abnormality on
LV angiography and had had successful PPCI within 24 h of symptom on-
set, defined as TIMI 3 flow in the infarct-related artery. Inclusion and ex-
clusion criteria are detailed in Supplementary material online, Methods.
Randomization and treatment
Following informed consent all participants underwent bone marrow
harvest from the iliac crest under local anaesthesia as soon as possible
after index PPCI (maximum time of 18 h allowing the recruitment of pa-
tients admitted out of hours). The aspirate was sent to the local desig-
nated stem cell laboratory where randomization occurred using
dedicated trial software (IHD Clinical, Bishops Stortford, Herts, UK).
Participants were randomized to either receive autologous bone mar-
row cells (BMC group) or matching placebo (placebo group) in a 1:1
block randomization allocation. Participants, investigators, and treating
clinicians remained blinded to group assignment. The amount of bone
marrow harvested was standardized at 100 mL. Bone marrow was pro-
cessed as previously described.16 Briefly, BMC were isolated by density
gradient centrifugation, washed and resuspended at a final volume of
10 mL. Placebo infusion was made up as 10 mL sterile NaCl 0.9%
with 33 mL autologous whole bone marrow to match colour to the
BMC product. No heparin was included in the final solution. The
BMC/placebo product was infused into the infarct-related artery in
three fractions during stop flow conditions within 6 h of bone marrow
harvest.12
Endpoints and definitions
The primary endpoint was absolute change in global LVEF assessed by
advanced cardiac imaging at 1 year compared with baseline. Secondary
imaging endpoints included changes in left ventricular volumes, area at
risk (AAR) defined as myocardial oedema mass/LV mass and infarct
size defined as infarcted LV mass/LV mass from baseline to 3 months
and 1 year and change in global ejection fraction by LV angiography at
6 months. Other secondary endpoints included change in NT-proBNP
levels (UK centres only), New York Heart Association (NYHA) classi-
fication, quality of life scoring (UK centres only), and major adverse car-
diac events (MACE): all-cause mortality, recurrent AMI as per the
universal definition of myocardial infarction,17 all coronary revasculari-
sation (target vessel or non-target vessel). All adverse events were re-
ported to 1 year and trial safety monitored by an independent Data and
Safety Monitoring Board.
Advanced cardiac imaging
Advanced cardiac imaging included cardiovascular magnetic resonance
(CMR) or cardiac computed tomography (CT) for those unable to
undergo CMR performed at 3 days post-PPCI (baseline), 3 months,
and 1 year. Multi-phase cardiac data sets with full left ventricular cover-
age were acquired using standard protocols.18 The standard error of
measurement of CMR and CT was 1.93 and 2.3%, respectively. The
scans were anonymized, batched, and analysed (CVI42, Circle Cardio-
vascular Imaging Inc., Calgary, Canada) in a blinded fashion by two ex-
perienced operators. Briefly, each CMR examination used cine-CMR
for ventricular volumes and function, T2-weighted imaging for myocar-
dial oedema and delayed enhancement CMR for infarct size assessment.
All cardiac CT analysis was performed using specialized cardiac CT cir-
culation software with intraventricular tracings of end systolic and end
diastolic timings. For full details of imaging protocols, see Supplementary
material online, Methods.
Left ventricular angiography
Participants underwent LV angiography and quantitative left ventricular
(QLV) analysis at the time of index PPCI and at 6 months.
Statistical design and analysis
The study was powered to the primary endpoint of change in LVEF at 1
year measured by CMR. The sample size was calculated using a two-
sample t-test statistic to detect an improvement in LVEF of 6% with a
power of 90% and significance level of 5%, based on previous cell ther-
apy Phase I/II trials.19 The assumption was made that there would be
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little (,1%) improvement in the control group as previously shown.19
Accounting for an estimated drop-out of 25% at 1 year, we aimed to
recruit a total of 100 participants to the study.
Analysis was based on the intention-to-treat principle. Baseline vari-
ables were summarized for each group. Continuous variables are pre-
sented as means+ SD or median+ interquartile range (IQR) and
categorical variables are presented as percentages. 95% confidence in-
tervals (CIs) are given. P-values are two sided with a value of,0.05 con-
sidered to indicate statistical significance. Within-group comparisons
were performed using the paired t-test and repeated measures analysis
of variance (ANOVA) adjusted for multiple comparison. Between-
group comparisons were performed using the unpaired t-test. All
statistical analyses were performed using SPSS version 19 (IBM Corp.
Armonk, NY, USA) and graphs produced using Graphpad Prism version
5.0 (GraphPad Software, San Diego, CA, USA).
Role of the funding source
No role of sponsor/funders in design or conduct of study.
Results
Between 19 March 2008 and 5 March 2013, 984 patients with sus-
pected ST elevation AMI were screened at five recruitment centres.
Of these patients, 884 were excluded for: non-LAD culprit vessel
(n ¼ 506), no anterior wall motion abnormality on LV angiogram
(n ¼ 78), patient intubated/on inotropes (n ¼ 61), delayed presen-
tation (n ¼ 59), age ,18 or .80 (n ¼ 49), and LV angiogram not
performed (n ¼ 39) (Figure 1). A total of 100 patients were re-
cruited with 92 reaching the 1 year primary endpoint.
The mean age was 56.5+ 10.5 years, and 87% were male.
At baseline, the groups were similar with regards to age, sex, med-
ical history, acute management, and findings on index angiography
(Table 1). The median time from PPCI to intracoronary infusion
was similar between the BMC group (532 min., range 403–1312)
and the placebo group (583 min, range 458–1276), P-value: 0.74.
Characterization of the cell therapy
product
The total mononuclear cell count in the cell product was
59.8 × 106+ 59.9 with a mean percentage of viable cells of
97.6+ 1.3 (Supplementary material online, Table S1). The mean
number of CD34+ cells in the cell product (as a measure of stem-
like potential of the BMC population) was 1.9 × 106+ 1.5. The pla-
cebo product contained 33 mL autologous whole bone marrow
having an estimated mononuclear cell count of 20 × 103 cells/mL
and CD34+ cell count of 20 cells/mL.
Left ventricular ejection fraction
Ninety-six participants underwent CMR assessment of cardiac func-
tion and two participants cardiac CT assessment. Baseline measure-
ment of LVEF was similar in the BMC and placebo group (47.8+ 9.4
and 48.9+ 9.7%, respectively) (Table 1). Analysis of paired data re-
vealed that global LVEF increased significantly in the BMC group by
5.1% from 47.5+ 9.2% at baseline to 52.6+ 10.5% at 1 year
(P, 0.0001) and in the placebo group by 2.8% from 49.2+ 9.6%
at baseline to 52.0+ 9.1% at 1 year (P ¼ 0.0019) (Figure 2A). In a
post hoc analysis, although there was a 2.2% (95% CI: 20.5 to 5.0;
P ¼ 0.10) absolute between-group difference in LVEF at 1 year
favouring the BMC group, this did not reach statistical significance
(Supplementary material online, Table S2).
Within-group changes at 3 months reveal a significant early in-
crease in LVEF in the BMC group (5.7%, P ¼ 0.0048) not seen in
the placebo group (1.6%, P ¼ 0.34). The significant change in LVEF
at 3 months which is maintained to 1 year in the BMC group is re-
flected in the repeated measures ANOVA analysis where the overall
change in LVEF is significant (P ¼ 0.0028) compared with the pla-
cebo group (P ¼ 0.071) (Figure 2B).
There were no within-group or between-group differences ob-
served in LV end systolic volume, LV end diastolic volume or cardiac
output at either 3 months or 1 year (Supplementary material online,
Table S2).
Infarct size, area at risk and myocardial
salvage
Infarct size at Day 3 was smaller in the BMC group than in the pla-
cebo group (25.4%; 95% CI:29.4 to21.4; P ¼ 0.0084). There was
a greater reduction in infarct size in the placebo group compared
with the BMC group over time (4.1%; 95% CI: 0.3 – 7.9;
P ¼ 0.033). The AAR decreased from baseline to 1 year in both
the BMC group by 32.5% (32.8+ 9.6–0.3+ 1.0%; P, 0.0001),
and in the placebo group by 33.3% (34.3+ 14.1 – 1.1+ 3.5%;
P, 0.0001) (Supplementary material online, Table S2).
Myocardial salvage index was calculated as the ratio of infarct size
and AAR.20 At Day 3, the BMC group showed a greater myocardial
salvage index compared with the placebo group (0.1%; 95% CI: 0.0–
0.2; P ¼ 0.048) (Supplementary material online, Table S2).
Left ventricular function by left ventricular
angiography
Global LVEF increased over 6 months in the BMC group by 7.1%
(49.2+11.1–56.4+14.9%; P ¼ 0.0007) and in the placebo group
by 5.0% (52.4+ 10.3–57.4+ 12.1%; P ¼ 0.012). There was a cor-
relation between QLV LVEF and CMR LVEF in both groups (Supple-
mentary material online, Table S3 and Figure S1).
Plasma NT-proBNP concentration
Plasma NT-proBNP was measured at baseline and 1 year and results
underwent logarithmic transformation due to non-normal distribu-
tion. There was a similar within-group decrease in NT-proBNP at 1
year in the BMC group (1334+ 1920–337.6+ 615.2 pg/mL;
P, 0.0001) and the placebo group (894.6+ 994.7–214.3+
140.9 pg/mL; P ¼ 0.0002) (Supplementary material online, Table S4).
New York Heart Association
At 6 and 12 months .75% of participants had an NYHA I classifica-
tion. There was no difference between NYHA classification
between-groups.
Quality of life
The European Quality of Life-5 Dimensions index score showed an
improvement in symptoms in the placebo group over the first 6
months of 0.1 (0.7+ 0.3 to 0.8+ 0.3; P ¼ 0.030). Within the
BMC group, there was an improvement at 1 year, 0.1 (0.7+ 0.4
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to 0.8+ 0.2; P ¼ 0.040). The visual analogue scale showed similar
improvement in both groups at 1 year (Supplementary material
online, Table S5).
Major adverse cardiac events and safety
Overall, there were very few MACE (Supplementary material
online, Table S6) with a similar occurrence between-groups
Figure 1 Consort diagram. Flow chart of the study design summarizing flow of participants through the trial.
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(P ¼ 0.95) (Supplementary material online, Figure S2). There were
no deaths in the placebo group whilst one patient died in the
BMC group from myocardial infarction at 6 months. No cases of
distal coronary artery occlusion occurred during intracoronary
infusion; however, two participants underwent further coronary
intervention at this time. Two participants had ventricular fibrillation
between bone marrow harvest and infusion and were cardioverted
successfully. Safety events are fully detailed in Supplementary
material online, Table S6, importantly there are no significant
between-group differences.
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Table 1 Baseline characteristics of the study population
Placebo group (n5 45) BMC group (n5 55) P-value
Age (year), mean+ SD 56.7+10.7 56.4+10.4 0.89
Sex (M/F), n) 41/4 46/9 0.27
Ethnicity (Caucasian) (n, %) 36 (80%) 47 (85.5%) 0.82
Medical history
Hypertension (n, %) 12 (26.7%) 24 (43.6%) 0.080
Hypercholesterolaemia (n, %) 10 (22.2%) 19 (34.5%) 0.18
Diabetes mellitus (n, %) 4 (8.8%) 6 (10.9%) 0.74
Active smoker (n, %) 24 (53.3%) 27 (49.0%) 0.74
Previous MI (n, %) 1 (2.2%) 1 (1.8%) 0.89
Previous PCI (n, %) 0 (0%) 1 (1.8%) 0.37
Family history (n, %) 13 (28.8%) 17 (30.9%) 0.83
Medical therapy
Aspirin (n, %) 45 (100%) 55 (100%) 1.0
Clopidogrel (n, %) 39 (86.7%) 50 (90.9%) 0.68
Prasugrel (n, %) 4 (8.9%) 3 (5.5%) 0.70
Ticagrelor (n, %) 2 (4.4%) 2 (3.6%) 1.0
Heparin (n, %) 40 (88.9%) 50 (90.9%) 0.75
Bivalirudin (n, %) 5 (11.1%) 5 (9.1%) 0.75
GP iib/iiia inhibitors (n, %) 33 (73%) 44 (80%) 0.63
DES used (n, %) 32 (71%) 36 (65%) 0.29
Concomitant PCI performed (n, %) 1 (2.2%) 3 (5.5%) 0.62
Baseline observations
Blood pressure (diastolic/systolic), mean 138.6/85.6 138.0/83.9 0.89/0.62
Pulse (bpm), mean+ SD 84.5+26.1 80.3+19.8 0.44
BMI (kg/m2), mean+ SD 27.1+4.3 26.7+3.1 0.58
CCS .1 (n, %) 1 (2.2%) 5 (9.1%) 0.22
NYHA .I (n, %) 3 (6.7%) 4 (7.3%) 1.0
Angiographic findings
BARI score (%) 35.6 (33.0–38.0) 35.6 (33.1–38.1) 0.98
APPROACH score (%) 37.1 (34.9–39.3) 38.5 (36.4–40.6) 0.37
TIMI flow ,2 (n, %) 35 (77.8%) 38 (60%) 0.37
Timings
Chest pain to PCI (min), median (IQR) 193.0 (145.5–320.5) 233 (155.0–348) 0.23
Door to PCI time (min), median (IQR) 36.0 (26.0–55.5) 40.0 (32.0–58.0) 0.22
PCI to BM aspiration time (min), median (IQR) 230.0 (112.0–966.0) 172.0 (105.0–976.0) 0.61
PCI to reinfusion (min), median (IQR) 583.0 (458.0–1276) 532.0 (403.0–1312) 0.74
BM aspiration to infusion (min), median (IQR) 313.0 (287.0–374.0) 323.0 (290.0–370.0) 0.41
Baseline LV function (CMR/CT)
LVEF (%) 48.9 (45.9–51.9) 47.8 (45.2–50.3) 0.56
LVEDV (mL) 159.6 (149.5–169.7) 154.5 (145.5–163.4) 0.44
LVESV (mL) 81.4 (74.0–88.8) 81.8 (74.7–89.0) 0.93
Values are mean (95% CI).
BMI, body mass index (weight (kg)/height2 (m)); BM, bone marrow; BARI, Bypass Angioplasty Revascularization Investigation Myocardial Jeopardy Index; APPROACH, Alberta
Provincial Project for Outcome Assessment in Coronary Heart Disease score; DES, drug eluting stent; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end
systolic volume.
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Discussion
REGENERATE-AMI is the first randomized controlled trial to inves-
tigate if the early administration of BMC following revascularization
for AMI, results in improved LVEF. Here the median time between
PPCI and cell delivery was under 10 h, a time point closest to that
used in successful preclinical work and previously not tested.4
REGENERATE-AMI demonstrates a significant improvement in
LVEF at 1 year with a 5.1% increase in LVEF in the BMC group
and a 2.8% increase in LVEF in the placebo group. Whilst these
were significant within-group improvements, the between-group
improvement favouring BMC was small and the trial therefore
failed to achieve its primary endpoint. There was no between-group
difference in secondary endpoints or safety endpoints. There was,
however, a greater reduction in infarct size over 1 year in the pla-
cebo group compared with the BMC group.
Secondary endpoint analysis revealed a significantly smaller in-
farct size coupled with a significantly increased myocardial salvage
index in the BMC group at Day 3 compared with the placebo group.
These factors are known to be associated with AMI prognosis.20 As
there was no significant difference in LVEF on angiography at PPCI, it
could be suggested that the observed reduced infarct size and in-
creased myocardial salvage were a result of BMC delivery. Interest-
ingly, participants in the BMC group also had a higher angiographic
risk score and a 40 min longer time from symptom onset to PPCI
which should have resulted in a larger infarct size at the baseline
scan. It is possible that intracoronary delivery of BMC at this early
time point plays a role in limiting ischaemia-reperfusion injury which
is estimated to account for up to 50% of final infarct size.3 Bone mar-
row mononuclear cells produce a variety of cytokines, chemokines,
and growth factors that promote myocardial repair and their pro-
duction is increased under conditions of hypoxic stress.21 It could
Figure 2 Endpoint analysis of left ventricular ejection fraction. Box and whisker plots (median and range, mean shown by +) including individual
data points of left ventricular ejection fraction measured at (A) baseline and 1 year (significance measured by paired t-test); (B) baseline, 3 months,
and 1 year (significance measured by repeated measures analysis of variance). Participant groups (a) intracoronary placebo infusion, (b) intracor-
onary BMC infusion.
The REGENERATE-AMI clinical trial 261
therefore be hypothesized that secretion of these reparative para-
crine factors is upregulated in the extensive myocardial hypoxia
and inflammation present in the first 24 h following AMI.
The hypothesis that BMC promote early recovery of myocardial
function is further supported by the early within BMC group im-
provement in LVEF at 3 months (47.5–53.3%, P ¼ 0.0048) which
was not seen in the placebo group. This difference favouring cell
therapy is similar to the results seen at 6 months in the early trials
upon which the assumptions were made for the design of
REGENERATE-AMI.19 Although this early improvement in LVEF
was maintained in the BMC group a later increase in LVEF in the
placebo group meant that the difference between the two
groups became small at 1 year, which has also been found in
medium-term follow-up of previous trials.6,7 This as well as the
fact that infarct remodelling is thought to be complete at 1 year
provided the rationale to assess the primary endpoint for
REGENERATE-AMI at 1 year.
Perhaps most importantly, REGENERATE-AMI shows that early
infusion of stem cells in patients who have recently undergone PPCI
(median—within 10 h) is safe. The potential of post-PPCI patients to
become unstable within the first 24 h is well known.22 Therefore,
cell delivery at this early stage may be limited by arrthymogenic
risk of injecting into a hostile myocardium with extensive oedema,
inflammation and microvascular obstruction, distal coronary embol-
ization and reduction in coronary flow. In addition heavy antiplatelet
and anticoagulant load may lead to bleeding. We showed a low rate
of bleeding complications, no distal coronary occlusion, and the two
participants who had ventricular arrhythmias were successfully car-
dioverted to sinus rhythm. The importance of assessing this time
point was to be able to deliver cell therapy to patients following
AMI within their standard 48 h hospital stay.23 We have shown
that the delivery of BMC therapy is highly feasible within this time-
frame without prolonging hospitalization. Cell therapy delivered at
Days 3–7 or later might raise logistical concerns regarding its imple-
mentation into standard practice.
Despite evidence of positive effects of BMC therapy,
REGENERATE-AMI failed to achieve its primary endpoint of an ab-
solute improvement in LVEF of 6% in BMC-treated patients com-
pared with placebo at 1 year. This was based on an early phase II
trial and reflects the time at which REGENERATE-AMI was de-
signed. A recent meta-analysis demonstrates a BMC conferred im-
provement in LVEF of 3.96%11 which may have been a more realistic
estimation. A larger sample size may have allowed the difference to
become significant but would have led to questions regarding the
size of the effect and its clinical relevance. Another limitation of
the trial is the relatively high ejection fractions seen at the baseline
scan—this was a direct result of the examination of the early time
point that meant that inclusion criteria were based on angiographic
wall motion abnormality (i.e. some evidence of damage) and not 3D
cross-sectional imaging which was not logistically possible if the aim
was to reinfuse within 24 h. The trial therefore enrolled a relatively
low proportion of participants with significantly impaired LVEF
(,45%), a group shown to derive greatest benefit from BMC ther-
apy.11,12 Cardiovascular magnetic resonance was performed at Day
3 post-infusion as this time point is considered to be representative
of final infarct size.24 However, as there was no comparable imaging
performed at the time of infusion it is not possible to conclusively
attribute between-group differences in infarct size and myocardial
salvage index at Day 3 to delivery of BMC or placebo.
REGENERATE-AMI uses an LVEF as a surrogate marker for the
primary endpoint; however, the relationship between LVEF and
hard clinical outcomes of mortality is not well defined. Furthermore,
as both placebo and BMC groups had intracoronary injection, it
might be hypothesized that improvement in LVEF in both groups
was a result of ischaemic post-conditioning rather than a specific ef-
fect of the BMC itself. Whether there is ultimately an adjunctive
benefit of BMC delivery in AMI will only definitively be addressed
by a study that is powered to detect differences in mortality end-
points with a comparison with standard AMI care. The BAMI trial
(BAMI, http://www.bami-fp7.eu) is the first Phase III trial designed
to do this by enrolling 3000 participants with all-cause mortality
at 5 years as the primary endpoint.
Conclusion
REGENERATE-AMI demonstrates that intracoronary delivery of
autologous BMC at an early time point (,24 h) after successful
PPCI for anterior AMI leads to an insignificant improvement in LV
function compared with placebo at 1 year. However, BMC therapy
was associated with a reduction in infarct size and an increased myo-
cardial salvage. Importantly, REGENERATE-AMI demonstrates the
safety and feasibility of early intracoronary injection of BMC which
supports the delivery of cell therapy within the timeframe of stand-
ard AMI hospitalization.
Supplementary material
Supplementary material is available at European Heart Journal online.
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